Perception of various stakeholders regarding clinical drug trial industry in India

Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. There is an urgent need for introspection and corrective actions. An online surve...

Full description

Saved in:
Bibliographic Details
Published in:Perspectives in clinical research 2011-07, Vol.2 (3), p.86-89
Main Authors: Parikh, Rakesh M, Pandia, Kirti, Goyal, Mahesh, Sharma, Meenakshi, Dolima, M S
Format: Article
Language:English
Subjects:
Clinical drug trials in India
Clinical trials
Conferences, meetings and seminars
ethical issues
Growth
hurdles in clinical drug trials
investigator training
Original
Pharmaceutical industry
regulatory delay
Scientific societies
Stakeholders
Training
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4295-4ef92bed035b25dc08afb6f36eb5ea51b82154dda79ad40bbe11f0691a773e863
cites
container_end_page 89
container_issue 3
container_start_page 86
container_title Perspectives in clinical research
container_volume 2
creator Parikh, Rakesh M
Pandia, Kirti
Goyal, Mahesh
Sharma, Meenakshi
Dolima, M S
description Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. There is an urgent need for introspection and corrective actions. An online survey was conducted among various stakeholders from clinical drug trial industry in India regarding their perception about clinical drug trial industry in India. Respondents were requested to rate training of investigator sites, industry, performance of regulatory, etc. Majority of respondent felt that the clinical drug trial industry in India is growing, though India is not utilizing its full potential. Lack of trained investigators and delay in regulatory approvals came out as biggest hurdles. Urgent steps need to be taken in terms of proper training of all stakeholders. Regulatory bodies ought to bring about some radical changes in the system so as to match the other competing nations.
doi_str_mv 10.4103/2229-3485.83225
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a5fee00396f84ef48fb97019fbf0ec6a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A263217101</galeid><doaj_id>oai_doaj_org_article_a5fee00396f84ef48fb97019fbf0ec6a</doaj_id><sourcerecordid>A263217101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4295-4ef92bed035b25dc08afb6f36eb5ea51b82154dda79ad40bbe11f0691a773e863</originalsourceid><addsrcrecordid>eNptUlFrFDEQXkSxpfbZN1kQ9OmuSTbJJi9CKVUPCoroc8gmk72ce8mZ7Bb6783enbUnJg8ZZr75ZvjyVdVrjJYUo-aKECIXDRVsKRpC2LPqfJ9hVIjnx3iunlWXOW9QOZRxzunL6oxgIVshyHn17SskA7vRx1BHV9_r5OOU6zzqn7COg4WU6wS9TtaHvjaDD97oobZp6usx-RL6YKc8pocS1KtgvX5VvXB6yHB5fC-qHx9vv998Xtx9-bS6ub5bGEokW1BwknRgUcM6wqxBQruOu4ZDx0Az3AmCGbVWt1JbiroOMHaIS6zbtgHBm4tqdeC1UW_ULvmtTg8qaq_2iZh6pdPozQBKMweAUCO5E2UuFa6TLcLSdQ6B4bpwfThw7aZuC9ZAGJMeTkhPK8GvVR_vVYOZJJgWgvdHghR_TZBHtfXZwDDoAEVQJYRAEgk5r_32H-QmTikUpRQWjIuWY0n-onpd9vfBxTLWzJzqmvCG4BYjXFDL_6DKtbD1JgZwvuRPGt49aViDHsZ1jsM0_38-BV4dgCbFnBO4Ry0wUrP71OwvNftL7d1XOt48lfAR_8drzW_ZltNs</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1856876192</pqid></control><display><type>article</type><title>Perception of various stakeholders regarding clinical drug trial industry in India</title><source>Publicly Available Content (ProQuest)</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Parikh, Rakesh M ; Pandia, Kirti ; Goyal, Mahesh ; Sharma, Meenakshi ; Dolima, M S</creator><creatorcontrib>Parikh, Rakesh M ; Pandia, Kirti ; Goyal, Mahesh ; Sharma, Meenakshi ; Dolima, M S</creatorcontrib><description>Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. There is an urgent need for introspection and corrective actions. An online survey was conducted among various stakeholders from clinical drug trial industry in India regarding their perception about clinical drug trial industry in India. Respondents were requested to rate training of investigator sites, industry, performance of regulatory, etc. Majority of respondent felt that the clinical drug trial industry in India is growing, though India is not utilizing its full potential. Lack of trained investigators and delay in regulatory approvals came out as biggest hurdles. Urgent steps need to be taken in terms of proper training of all stakeholders. Regulatory bodies ought to bring about some radical changes in the system so as to match the other competing nations.</description><identifier>ISSN: 2229-3485</identifier><identifier>EISSN: 2229-5488</identifier><identifier>DOI: 10.4103/2229-3485.83225</identifier><identifier>PMID: 21897882</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Clinical drug trials in India ; Clinical trials ; Conferences, meetings and seminars ; ethical issues ; Growth ; hurdles in clinical drug trials ; investigator training ; Original ; Pharmaceutical industry ; regulatory delay ; Scientific societies ; Stakeholders ; Training</subject><ispartof>Perspectives in clinical research, 2011-07, Vol.2 (3), p.86-89</ispartof><rights>COPYRIGHT 2011 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications &amp; Media Pvt Ltd Jul-Sep 2011</rights><rights>Copyright: © Perspectives in Clinical Research 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4295-4ef92bed035b25dc08afb6f36eb5ea51b82154dda79ad40bbe11f0691a773e863</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159214/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1856876192?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21897882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parikh, Rakesh M</creatorcontrib><creatorcontrib>Pandia, Kirti</creatorcontrib><creatorcontrib>Goyal, Mahesh</creatorcontrib><creatorcontrib>Sharma, Meenakshi</creatorcontrib><creatorcontrib>Dolima, M S</creatorcontrib><title>Perception of various stakeholders regarding clinical drug trial industry in India</title><title>Perspectives in clinical research</title><addtitle>Perspect Clin Res</addtitle><description>Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. There is an urgent need for introspection and corrective actions. An online survey was conducted among various stakeholders from clinical drug trial industry in India regarding their perception about clinical drug trial industry in India. Respondents were requested to rate training of investigator sites, industry, performance of regulatory, etc. Majority of respondent felt that the clinical drug trial industry in India is growing, though India is not utilizing its full potential. Lack of trained investigators and delay in regulatory approvals came out as biggest hurdles. Urgent steps need to be taken in terms of proper training of all stakeholders. Regulatory bodies ought to bring about some radical changes in the system so as to match the other competing nations.</description><subject>Clinical drug trials in India</subject><subject>Clinical trials</subject><subject>Conferences, meetings and seminars</subject><subject>ethical issues</subject><subject>Growth</subject><subject>hurdles in clinical drug trials</subject><subject>investigator training</subject><subject>Original</subject><subject>Pharmaceutical industry</subject><subject>regulatory delay</subject><subject>Scientific societies</subject><subject>Stakeholders</subject><subject>Training</subject><issn>2229-3485</issn><issn>2229-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUlFrFDEQXkSxpfbZN1kQ9OmuSTbJJi9CKVUPCoroc8gmk72ce8mZ7Bb6783enbUnJg8ZZr75ZvjyVdVrjJYUo-aKECIXDRVsKRpC2LPqfJ9hVIjnx3iunlWXOW9QOZRxzunL6oxgIVshyHn17SskA7vRx1BHV9_r5OOU6zzqn7COg4WU6wS9TtaHvjaDD97oobZp6usx-RL6YKc8pocS1KtgvX5VvXB6yHB5fC-qHx9vv998Xtx9-bS6ub5bGEokW1BwknRgUcM6wqxBQruOu4ZDx0Az3AmCGbVWt1JbiroOMHaIS6zbtgHBm4tqdeC1UW_ULvmtTg8qaq_2iZh6pdPozQBKMweAUCO5E2UuFa6TLcLSdQ6B4bpwfThw7aZuC9ZAGJMeTkhPK8GvVR_vVYOZJJgWgvdHghR_TZBHtfXZwDDoAEVQJYRAEgk5r_32H-QmTikUpRQWjIuWY0n-onpd9vfBxTLWzJzqmvCG4BYjXFDL_6DKtbD1JgZwvuRPGt49aViDHsZ1jsM0_38-BV4dgCbFnBO4Ry0wUrP71OwvNftL7d1XOt48lfAR_8drzW_ZltNs</recordid><startdate>201107</startdate><enddate>201107</enddate><creator>Parikh, Rakesh M</creator><creator>Pandia, Kirti</creator><creator>Goyal, Mahesh</creator><creator>Sharma, Meenakshi</creator><creator>Dolima, M S</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><general>Medknow Publications Pvt Ltd</general><general>Wolters Kluwer Medknow Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>201107</creationdate><title>Perception of various stakeholders regarding clinical drug trial industry in India</title><author>Parikh, Rakesh M ; Pandia, Kirti ; Goyal, Mahesh ; Sharma, Meenakshi ; Dolima, M S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4295-4ef92bed035b25dc08afb6f36eb5ea51b82154dda79ad40bbe11f0691a773e863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Clinical drug trials in India</topic><topic>Clinical trials</topic><topic>Conferences, meetings and seminars</topic><topic>ethical issues</topic><topic>Growth</topic><topic>hurdles in clinical drug trials</topic><topic>investigator training</topic><topic>Original</topic><topic>Pharmaceutical industry</topic><topic>regulatory delay</topic><topic>Scientific societies</topic><topic>Stakeholders</topic><topic>Training</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parikh, Rakesh M</creatorcontrib><creatorcontrib>Pandia, Kirti</creatorcontrib><creatorcontrib>Goyal, Mahesh</creatorcontrib><creatorcontrib>Sharma, Meenakshi</creatorcontrib><creatorcontrib>Dolima, M S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Perspectives in clinical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parikh, Rakesh M</au><au>Pandia, Kirti</au><au>Goyal, Mahesh</au><au>Sharma, Meenakshi</au><au>Dolima, M S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perception of various stakeholders regarding clinical drug trial industry in India</atitle><jtitle>Perspectives in clinical research</jtitle><addtitle>Perspect Clin Res</addtitle><date>2011-07</date><risdate>2011</risdate><volume>2</volume><issue>3</issue><spage>86</spage><epage>89</epage><pages>86-89</pages><issn>2229-3485</issn><eissn>2229-5488</eissn><abstract>Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. There is an urgent need for introspection and corrective actions. An online survey was conducted among various stakeholders from clinical drug trial industry in India regarding their perception about clinical drug trial industry in India. Respondents were requested to rate training of investigator sites, industry, performance of regulatory, etc. Majority of respondent felt that the clinical drug trial industry in India is growing, though India is not utilizing its full potential. Lack of trained investigators and delay in regulatory approvals came out as biggest hurdles. Urgent steps need to be taken in terms of proper training of all stakeholders. Regulatory bodies ought to bring about some radical changes in the system so as to match the other competing nations.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>21897882</pmid><doi>10.4103/2229-3485.83225</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2229-3485
ispartof Perspectives in clinical research, 2011-07, Vol.2 (3), p.86-89
issn 2229-3485
2229-5488
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a5fee00396f84ef48fb97019fbf0ec6a
source Publicly Available Content (ProQuest); IngentaConnect Journals; PubMed Central
subjects Clinical drug trials in India
Clinical trials
Conferences, meetings and seminars
ethical issues
Growth
hurdles in clinical drug trials
investigator training
Original
Pharmaceutical industry
regulatory delay
Scientific societies
Stakeholders
Training
title Perception of various stakeholders regarding clinical drug trial industry in India
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A36%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perception%20of%20various%20stakeholders%20regarding%20clinical%20drug%20trial%20industry%20in%20India&rft.jtitle=Perspectives%20in%20clinical%20research&rft.au=Parikh,%20Rakesh%20M&rft.date=2011-07&rft.volume=2&rft.issue=3&rft.spage=86&rft.epage=89&rft.pages=86-89&rft.issn=2229-3485&rft.eissn=2229-5488&rft_id=info:doi/10.4103/2229-3485.83225&rft_dat=%3Cgale_doaj_%3EA263217101%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4295-4ef92bed035b25dc08afb6f36eb5ea51b82154dda79ad40bbe11f0691a773e863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1856876192&rft_id=info:pmid/21897882&rft_galeid=A263217101&rfr_iscdi=true